As targeted radiation field heats up, AstraZeneca to acquire Fusion Pharmaceuticals in $2 billion deal; In small study, baby aspirin cuts fat buildup in liver disease patients

Taking stock of the drug industry, from the lab to the medicine chest

March 19, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Alastair Grant/AP STAT+ | As targeted radiation field heats up, AstraZeneca to acquire Fusion Pharmaceuticals in $2 billion deal The $2 billion deal is the latest sign that the radiopharmaceuticals field of cancer treatments is booming. By Andrew Joseph STAT+ | In small study, baby aspirin cuts fat buildup in liver disease patients Although more research is needed, the study suggests that baby aspirin could help some patients with metabolic liver disease, or MASLD.  By Isabella Cueto STAT+ | The methadone clinic monopoly: Opioid treatment chains backed by private equity are fighting calls for reform A first-of-its-kind analysis by STAT finds that a handful of private equity firms own nearly a third of U.S. methadone clinics. By Lev Facher

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser